Label: VITRASE- hyaluronidase, ovine injection, solution
- NDC Code(s): 24208-002-02
- Packager: Bausch & Lomb Incorporated
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: New Drug Application
Updated May 29, 2018
If you are a consumer or patient please visit this version.
- HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use VITRASE safely and effectively. See full prescribing information for VITRASE.
VITRASE ® (hyaluronidase injection) Ovine, for infiltration use, for interstitial use, for intramuscular use, for intraocular use, for peribulbar use, for retrobulbar use, for soft tissue use, and for subcutaneous use
Initial U.S. Approval: 2004
INDICATIONS AND USAGE
DOSAGE AND ADMINISTRATION
- Draw the desired amount of VITRASE into the syringe to obtain target hyaluronidase activity (USP Units) according to table. ( 2.1)
- Before adding VITRASE to a solution containing another drug check appropriate references regarding physical/chemical incompatibilities. ( 7)
- Subcutaneous Fluid Administration: Inject 200 Units of VITRASE prior to clysis. It will facilitate absorption of 1,000 mL or more of solution. The dosage of subcutaneous fluids administered depends upon the age, weight, clinical condition of the patient, and laboratory determinations. Rate and volume of subcutaneous fluid administration should not exceed those employed for intravenous infusion. ( 2.2, 8.4)
- Increasing absorption and dispersion of injected drugs: Add 50–300 Units (most typically 150 Units) of VITRASE to the injection solution. ( 2.3)
- Subcutaneous urography: With the patient prone, inject 75 Units of VITRASE subcutaneously over each scapula, followed by injection of the contrast medium at the same sites. ( 2.4)
DOSAGE FORMS AND STRENGTHS
Injection: 200 USP Units/mL in a single-dose vial (3)
WARNINGS AND PRECAUTIONS
Allergic and anaphylactic-like reactions have been reported, rarely. (6) To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb, a division of Valeant Pharmaceuticals North America LLC, at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
- Furosemide, benzodiazepines and phenytoin are incompatible with hyaluronidase. ( 7.1)
- Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs. ( 7.2)
- Local anesthetics: Hyaluronidase hastens onset and shortens duration of effect, increases incidence of systemic reactions. ( 7.3)
- Large doses of salicylates, cortisone, adrenocorticotropic hormone (ACTH), estrogens or antihistamines: Concomitant use may require larger amounts of hyaluronidase for equivalent dispersing effect. ( 7.4)
USE IN SPECIFIC POPULATIONS
Pediatric Use: The dosage of subcutaneous fluids administered is dependent upon the age, weight, and clinical condition of the patient. For premature infants or during the neonatal period, the daily dosage should not exceed 25 mL/kg of body weight, and the rate of administration should not be greater than 2 mL per minute. Special care must be taken in pediatric patients to avoid overhydration by controlling the rate and total volume of the infusion (2.2, 8.4).
See 17 for PATIENT COUNSELING INFORMATION.
- FULL PRESCRIBING INFORMATION: CONTENTS*
- Sections or subsections omitted from the full prescribing information are not listed.
- 1 INDICATIONS AND USAGE
1.1 Subcutaneous Fluid Administration (Hypodermoclysis)
VITRASE® (hyaluronidase injection) Ovine is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration.
1.2 Dispersion and Absorption of Injected Drugs
VITRASE is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs.
1.3 Subcutaneous Urography
VITRASE is indicated as an adjuvant in subcutaneous urography for improving resorption of radiopaque agents.
- 2 DOSAGE AND ADMINISTRATION
2.1 Important Administration Instructions
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
VITRASE should be administered as discussed below, since its effects relative to absorption and dispersion of other drugs are not produced when it is administered intravenously.
Draw the desired amount of VITRASE into the syringe to obtain the target Hyaluronidase Activity (USP Units) according to the table below.
Table 1: Amount of VITRASE Solution Withdrawn Per Target Hyaluronidase Activity
Activity (USP Units)
Volume Withdrawn from
After admixture with drug, store at 15° to 25°C (59° to 77°F) and use within 6 hours.
2.2 Dosage for Subcutaneous Fluid Administration (Hypodermoclysis)
Insert needle with aseptic precautions. With tip free and movable between skin and muscle, begin clysis; fluid should start in readily without pain or lump. Then inject VITRASE into rubber tubing close to needle.
An alternate method is to inject VITRASE under skin prior to clysis. 200 Units will facilitate absorption of 1,000 mL or more of solution. As with all parenteral fluid therapy, observe effect closely, with same precautions for restoring fluid and electrolyte balance as in intravenous injections. The dose, the rate of injection, and the type of solution (saline, glucose, Ringer’s, etc.) must be adjusted carefully to the individual patient. When solutions devoid of inorganic electrolytes are given by hypodermoclysis, hypovolemia may occur. This may be prevented by using solutions containing adequate amounts of inorganic electrolytes and/or controlling the volume and speed of administration.
VITRASE may be added to small volumes of solution (up to 200 mL), such as small clysis for infants or solutions of drugs for subcutaneous injection. For infants and children less than 3 years old, the volume of a single clysis should be limited to 200 mL; and in premature infants or during the neonatal period, the daily dosage should not exceed 25 mL/kg of body weight; the rate of administration should not be greater than 2 mL per minute. For older patients, the rate and volume of administration should not exceed those employed for intravenous infusion.
2.3 Dosage for Absorption and Dispersion of Injected Drugs
Absorption and dispersion of other injected drugs may be enhanced by adding 50–300 Units, most typically 150 Units of VITRASE to the injection solution.
2.4 Dosage for Subcutaneous Urography
The subcutaneous route of administration of urographic contrast media is indicated when intravenous administration cannot be successfully accomplished, particularly in infants and small children. With the patient prone, 75 Units of VITRASE are injected subcutaneously over each scapula, followed by injection of the contrast medium at the same sites.
- 3 DOSAGE FORMS AND STRENGTHS
Injection: 200 USP Units/mL in a single-dose vialClose
- 4 CONTRAINDICATIONS
VITRASE is contraindicated in patients with known hypersensitivity to hyaluronidase or any other ingredient in the formulation. A preliminary skin test for hypersensitivity to VITRASE can be performed. The skin test is made by intradermal injection of approximately 0.02 mL (4 Units) of a 200 Units/mL solution [see Dosage and Administration (2)]. A positive reaction consists of a wheal with pseudopods appearing within 5 minutes and persisting for 20 to 30 minutes and accompanied by localized itching. Transient vasodilation at the site of the test, i.e., erythema, is not a positive reaction.
Discontinue VITRASE if sensitization occurs.Close
- 5 WARNINGS AND PRECAUTIONS
5.1 Spread of Localized Infection
Hyaluronidase should not be injected into or around infected or acutely inflamed area because of the danger of spreading to a localized infection. Hyaluronidase should not be used to reduce the swelling of bites or stings.
5.3 Enzyme Inactivation with Intravenous Administration
VITRASE should not be used for intravenous injections because the enzyme is rapidly inactivated.
- 6 ADVERSE REACTIONS
The following adverse reactions have been identified during post-approval use of hyaluronidase products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most frequently reported adverse reactions have been local injection site reactions.
Hyaluronidase has been reported to enhance the adverse reactions associated with co-administered drug products. Edema has been reported most frequently in association with hypodermoclysis.
Allergic reactions (e.g., urticaria, angioedema) have been reported in less than 0.1% of patients receiving hyaluronidase. Anaphylactic-like reactions following retrobulbar block or intravenous injections have occurred, rarely.Close
- 7 DRUG INTERACTIONS
It is recommended that appropriate references be consulted regarding physical or chemical incompatibilities before adding VITRASE to a solution containing another drug.
Furosemide, benzodiazepines and phenytoin have been found to be incompatible with hyaluronidase.
7.2 Drug-Specific Precautions
Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs.
When considering the administration of any other drug with hyaluronidase, it is recommended that appropriate references first be consulted to determine the usual precautions for the use of the other drug.
7.3 Local Anesthetic Agent
When hyaluronidase is added to a local anesthetic agent, it hastens the onset of analgesia and tends to reduce the swelling caused by local infiltration, but the wider spread of the local anesthetic solution increases its absorption; this shortens its duration of action and tends to increase the incidences of systemic reaction.
7.4 Salicylates, Cortisone, ACTH, Estrogens, Antihistamines
Patients receiving large doses of salicylates, cortisone, adrenocorticotropic hormone (ACTH), estrogens, or antihistamines may require larger amounts of hyaluronidase for equivalent dispersing effect, since these drugs apparently render tissues partly resistant to the action of hyaluronidase.
- 8 USE IN SPECIFIC POPULATIONS
Human studies of hyaluronidase as an aid to conception and as an aid to delivery have been conducted without reports of maternal or fetal harm. Non‑human animal reproduction studies have not been conducted with VITRASE.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4%, and of miscarriage is 15 to 20%, of clinically recognized pregnancies.
Hyaluronidase has been used as a component to aid the in vitro fertilization of human eggs. Administration of hyaluronidase during labor was reported to cause no complications; no increase in blood loss or differences in cervical trauma were observed.
There is no information regarding the presence of VITRASEin human milk, the effects on breastfed infants, or the effects on milk production to inform risk of VITRASE to an infant during lactation. The developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for VITRASE, and any potential adverse effects on the breastfed infant from VITRASE.
8.4 Pediatric Use
The safety and effectiveness of VITRASE have been established in pediatric patients. Use of VITRASE in these patients is supported by evidence from adequate and well-controlled studies. Clinical hydration requirements for children can be achieved through administration of subcutaneous fluids facilitated with VITRASE.
The dosage of subcutaneous fluids administered is dependent upon the age, weight, and clinical condition of the patient as well as laboratory determinations. The potential for chemical or physical incompatibilities should be kept in mind [see Drug Interactions (7)].
The rate and volume of subcutaneous fluid administration should not exceed those employed for intravenous infusion. For premature infants or during the neonatal period, the daily dosage should not exceed 25 mL/kg of body weight, and the rate of administration should not be greater than 2 mL per minute.
During subcutaneous fluid administration, special care must be taken in pediatric patients to avoid over hydration by controlling the rate and total volume of the infusion [see Dosage and Administration (2.2)].
8.5 Geriatric Use
No overall differences in safety or effectiveness have been observed between elderly and younger adult patients.
- 11 DESCRIPTION
VITRASE® (hyaluronidase injection) Ovine is a preparation of purified ovine testicular hyaluronidase, a protein enzyme. The exact chemical structure of this enzyme is unknown.
VITRASE (hyaluronidase injection) is supplied as a sterile, nonpreserved, clear, colorless solution with a pH of 6.4 to 7.2 for infiltration use, for interstitial use, for intramuscular use, for intraocular use, for peribulbar use, for retrobulbar use, for soft tissue use, and for subcutaneous use. Each mL contains 200 USP Units of ovine hyaluronidase with 0.93 mg lactose monohydrate, 0.36 mg potassium phosphate dibasic, 0.23 mg potassium phosphate monobasic, and 9.0 mg sodium chloride.Close
- 12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Hyaluronidase is a spreading or diffusing substance, which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue, and of certain specialized tissues, such as the umbilical cord and vitreous humor. Hyaluronic acid is also present in the capsules of type A and C hemolytic streptococci. Hyaluronidase hydrolyzes hyaluronic acid by splitting the glucosaminidic bond between C1 of the glucosamine moiety and C4 of glucuronic acid. This temporarily decreases the viscosity of the cellular cement and promotes diffusion of injected fluids or of localized transudates or exudates, thus facilitating their absorption.
Hyaluronidase cleaves glycosidic bonds of hyaluronic acid and, to a variable degree, some other acid mucopolysaccharides of the connective tissue. The activity is measured in vitro by monitoring the decrease in the amount of an insoluble serum albumen-hyaluronic acid complex as the enzyme cleaves the hyaluronic acid component.
In the absence of hyaluronidase, material injected subcutaneously spreads very slowly. Hyaluronidase facilitates dispersion, provided local interstitial pressure is adequate to furnish the necessary mechanical impulse. Such an impulse is normally initiated by injected solutions. The rate and extent of dispersion and absorption is proportionate to the amount of hyaluronidase and the volume of solution.
The reconstitution of the dermal barrier removed by intradermal injection of hyaluronidase (over a range of 0.002 to 20 Units/mL) to adult humans indicated that at 24 hours the restoration of the barrier is incomplete and inversely related to the dosage of enzyme; at 48 hours the barrier is completely restored in all treated areas.
Results from an experimental study, in humans, on the influence of hyaluronidase in bone repair support the conclusion that this enzyme alone, in the usual clinical dosage, does not deter bone healing.
Knowledge of the mechanisms involved in the disappearance of injected hyaluronidase is limited. It is known, however, that the blood of a number of mammalian species including humans brings about the inactivation of hyaluronidase.
Studies have demonstrated that hyaluronidase is antigenic; repeated injections of relatively large amounts of this enzyme may result in the formation of neutralizing antibodies.
- 13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Animal studies have not been conducted to determine whether hyaluronidase has carcinogenic or mutagenic potential.
Adequate fertility studies have not been conducted in animals, however, it has been reported that testicular degeneration may occur from the production of organ-specific antibodies against this enzyme following repeated injections.
- 16 HOW SUPPLIED/STORAGE AND HANDLING
VITRASE® (hyaluronidase injection) is supplied as 200 USP Units/mL of sterile, nonpreserved, clear, colorless solution in a single-dose, 2 mL glass vial with a rubber stopper and aluminum seal.
VITRASE is supplied in the following packaging:
200 USP Units/mL in a single-dose vial (NDC 24208-002-03) available in a carton containing 2 single-dose vials (NDC 24208-002-02).
- Protect from light.
- Store unopened vial in refrigerator at 2° to 8°C (35° to 46°F).
- Do not freeze.
- 17 PATIENT COUNSELING INFORMATION
Reporting Adverse Reactions
Instruct patients to report adverse reactions including redness, swelling, itching, or pain at the injection site.
Interactions with Other Medications
Instruct patients to report if they are taking furosemide, benzodiazepines, phenytoin, dopamine and/or alpha agonists because these medications have been found to be incompatible with hyaluronidase.
Instruct patients to report if they are taking salicylates (e.g., aspirin), steroids (e.g., cortisone or estrogens) or antihistamines because larger amounts of hyaluronidase may be needed to achieve an equivalent dispersing effect.
Bausch + Lomb, a division of
Valeant Pharmaceuticals North America LLC
Bridgewater, NJ 08807 USA
Irvine, CA 92618 USA
Vitrase is a trademark of Bausch & Lomb Incorporated or its affiliates.
© Bausch & Lomb Incorporated
- PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – Vitrase Carton Label
200 USP UNITS/mL
NOT FOR IV USE
2 Single-Use Vials (Nonpreserved)
Contains 1.2 mL per vial
- INGREDIENTS AND APPEARANCE
hyaluronidase, ovine injection, solution
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:24208-002 Route of Administration SUBCUTANEOUS Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength HYALURONIDASE, OVINE (UNII: 64R4OHP8T0) (HYALURONIDASE, OVINE - UNII:64R4OHP8T0) HYALURONIDASE, OVINE 200 [USP'U] in 1 mL Inactive Ingredients Ingredient Name Strength POTASSIUM PHOSPHATE, MONOBASIC (UNII: 4J9FJ0HL51) 0.23 mg in 1 mL SODIUM CHLORIDE (UNII: 451W47IQ8X) 9.0 mg in 1 mL LACTOSE, UNSPECIFIED FORM (UNII: J2B2A4N98G) DIBASIC POTASSIUM PHOSPHATE (UNII: CI71S98N1Z) Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:24208-002-02 2 in 1 CARTON 02/01/2005 1 1.2 mL in 1 VIAL, SINGLE-USE; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA021640 02/01/2005 Labeler - Bausch & Lomb Incorporated (196603781) Establishment Name Address ID/FEI Business Operations Alliance Medical Products, Inc. (dba Siegfried Irvine) 102688657 ANALYSIS(24208-002) , LABEL(24208-002) , MANUFACTURE(24208-002) , PACK(24208-002)